Adamis gets U.S. approval to sell EpiPen rival, shares soar

(Reuters) - Adamis Pharmaceuticals on Thursday said it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that would compete with Mylan's widely used EpiPen, sending its shares up 50 percent.